Epidemiological findings and clinical outcomes of patients with inflammatory and non-inflammatory connective tissue diseases infected with COVID-19 omicron variant

Soleimani, Zahra; Esalatmanesh, Kamal; Azadchehr, Mohammad Javad; Khodaei, Sahar; Esalatmanesh, Roozbeh

doi:10.48307/FMSJ.2023.27.3.315

[Home ] [Archive]

[ فارسی ]

Main Menu

Home

Journal Information

Indexing Sources

Guide for Authors

Online Submission

Ethics

Articles archive

For Reviewers

Contact us

Basic and Clinical Biochemistry and Nutrition

DOAJ

CINAHL

EBSCO

IMEMR

ISC

Search in website

Receive site information

enamad

Volume 27, Issue 3 (August-September 2023)

Feyz Med Sci J 2023, 27(3): 315-325

Back to browse issues page

Epidemiological findings and clinical outcomes of patients with inflammatory and non-inflammatory connective tissue diseases infected with COVID-19 omicron variant

Zahra Soleimani

, Kamal Esalatmanesh

, Mohammad Javad Azadchehr

, Sahar Khodaei

, Roozbeh Esalatmanesh ^*

Student Research Committee, Kashan University of Medical Sciences, Kashan, I.R. Iran. , esalatr@gmail.com

Abstract: (720 Views)

Background: In late December 2019, COVID-19 has been reported in China. This study was conducted to investigate the epidemiological findings and clinical outcomes of patients with inflammatory and non-inflammatory connective tissue diseases infected with COVID-19 omicron variant.
Materials and Methods: In this cross-sectional study, the medical files of 159 connective tissue patients infected with COVID-19 Omicron variant referred to Shahid Beheshti Hospital in Kashan, Iran, were examined from winter 2021 to spring 2022. A checklist containing the epidemiological characteristics and clinical outcomes of the patients was completed and data analysis was done by SPSS software.
Results: Most of the patients were women (84.4%) and the mean age of the patients was 51.85 years. The most common underlying diseases were diabetes (18.9%) and hypertension (13.8%). Among the patients, 44.7% had rheumatoid arthritis, and osteoarthritis and lupus were in the next order with 15.7% and 10.7%, respectively. The most common clinical symptoms were myalgia (84.9%) and fever (78.6%). Also, 32.7% of patients had lymphopenia and 74.8% had high CRP. In addition, the results of chest CT scans were reported as moderate to severe in 42.7% of the patients. In addition, COVID-19 was severe in 41.5% of patients. Finally, Five patients (1.3%) died.
Conclusion: The clinical and laboratory findings related to the Omicron variant in the present study are similar to other variants of COVID-19. Nevertheless, the findings of lung CT scan images and mortality in the present study are higher than the delta variant of COVID-19.

Keywords: COVID-19, Omicron variant, inflammatory and Non-inflammatory connective tissue diseases, Outcome

Full-Text [PDF 309 kb] (326 Downloads)

Type of Study: Research | Subject: medicine, paraclinic
Received: 2023/05/9 | Revised: 2023/10/31 | Accepted: 2023/07/3 | Published: 2023/08/5

References

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506.

2. Ashour HM, Elkhatib WF, Rahman M, Elshabrawi HA. Insights into the recent 2019 novel corona virus (SARS-CoV-2) in light of past human coronavirus outbreaks. Pathogens 2020; 9: 186-200.

3. National Health Commission of China. The guidelines for diagnosis and treatment of novel coronavirus (2019‐nCoV) infected pneumonia (the sixth edition draft) issued by the National Health Commission of China.

4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-9.

5. Li M, Lei P, Zeng B, Li Z, Yu P, Fan B, et al. Coronavirus disease (COVID-19): spectrum of CT findings and temporal progression of the disease. Academic Radiol 2020; 27(5): 603-8.

6. Liu Y, Mao B, Liang S, Yang JW, Lu HW, Chai YH, et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur Respir J 2020; 55: 2001112.

7. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID‐19) in China. Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41(2): 145‐151.

8. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in china. N Engl J Med 2020.

9. Costa L, Tasso M, Scotti N, Mostacciuolo E, Girolimetto N, Foglia F, Del Puente A, Scarpa R, Caso F. Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort. Ann Rheumatic Dis 2021; 80(4): e46-.

10. Tariq S, Van Eeden C, Tervaert JWC, Osman MS. COVID-19, rheumatic diseases and immune dysregulation—a perspective. Clin Rheumatol 2021; 40(2): 433–42.

11. D’Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’. Ann Rheum Dis 2020; 79(9): 1156-62.

12. D’Silva KM, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace ZS, et al. COVID-19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study. Arthritis Rheumatol 2021; 73(6): 914-20.

13. Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, Rúa-Figueroa Í, Gonzalez-Gay MA, et al. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis 2020; 79(7): 988-90.

14. Espinosa G, Prieto-González S, Llevadot M, Marco-Hernández J, Martínez-Artuña A, Pérez-Isidro A, et al. The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia. Clin Rheumatol 2021; 40(5): 2057–63.

15. Sawalha AH, Zhao M, Coit P, Lu Q. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol 2020; 215: 108410.

16. Favalli EG, Gerosa M, Murgo A, Caporali R. Are patients with systemic lupus erythematosus at increased risk for COVID-19? Ann Rheum Dis 2021; 80(2): e25.

17. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020; 79(5): 667-8.

18. Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis 2021; 80(9): 1137-46.

19. Mahdavi AM, Varshochi M, Hajialilo M, Dastgiri S, Khabbazi R, Khabbazi A. Factors associated with COVID-19 and its outcome in patients with rheumatoid arthritis. Clin Rheumatol 2021; 1-5.

20. Parekh M, Platt P, Barnes J. Coronavirus latest news: EU suspends all flights to southern Africa over omicron Covid variant fears. Telegraph 2021; 26.

21. Bhoye S, Marakwad T. A Comparative Characteristics of Both Variants of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): Delta and Omicron. 2021.

22. He X, Hong W, Pan X, Lu G, Wei X. SARS‐CoV‐2 Omicron variant: characteristics and prevention. MedComm 2021; 2(4): 838-45.

23. Fall A, Eldesouki RE, Sachithanandham J, Morris CP, Norton JM, Gaston DC, et al. The displacement of the SARS-CoV-2 variant Delta with Omicron: An investigation of hospital admissions and upper respiratory viral loads. EBioMedicine 2022; 79: 104008.

24. Corriero A, Ribezzi M, Mele F, Angrisani C, Romaniello F, Daleno A, Loconsole D, Centrone F, Chironna M, Brienza N. COVID-19 variants in critically ill patients: A comparison of the Delta and Omicron variant profiles. Infectious Dis Reports 2022; 14(3): 492-500.

25. Bieber A, Brikman S, Novack L, Ayalon S, Abu-Shakra M, Zeller L, et al. SARS-CoV-2 infection among patients with autoimmune rheumatic diseases; comparison between the Delta and Omicron waves in Israel. InSeminars in Arthritis and Rheumatism 2023 Feb 1 (Vol. 58, p. 152129). WB Saunders.

26. Kawano Y, Patel NJ, Wang X, Cook CE, Vanni KM, Kowalski EN, et al. Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave. Ann Rheumatic Dis 2022; 81(12): 1742-9.

27. Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, et al. Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score. Clin Infect Dis 2020; 71(6): 1393-9.

28. Bahramnia M, Ramak N, Sangani A. The Role of Perceived Mental Stress in the Health of Suspected Cases of COVID-19. J Mil Med 2020; 22(2): 115-21.

29. Wu P, Hao X, Lau EH, Wong JY, Leung KS, Wu JT, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Euro Surveill 2020; 25(3): 2000044.

30. Soleimani Z, Rahimi H, Maleki N, Esalatmanesh R, Esalatmanesh K. Evaluation the epidemiologic of patients with COVID-19 delta variant admitted to Shahid Beheshti hospital in Kashan. Feyz 2022; 26(4): 483-90.‎ [in Persian]

31. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506.

32. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507-13.

Send email to the article author

Add your comments about this article

‎ 10.48307/FMSJ.2023.27.3.315

Mendeley

Zotero

RefWorks

Soleimani Z, Esalatmanesh K, Azadchehr M J, Khodaei S, Esalatmanesh R. Epidemiological findings and clinical outcomes of patients with inflammatory and non-inflammatory connective tissue diseases infected with COVID-19 omicron variant. Feyz Med Sci J 2023; 27 (3) :315-325
URL: http://feyz.kaums.ac.ir/article-1-4876-en.html

This open access journal is licensed under a Creative Commons Attribution-NonCommercial ۴.۰ International License. CC BY-NC ۴. Design and publishing by Kashan University of Medical Sciences.
Copyright ۲۰۲۳© Feyz Medical Sciences Journal. All rights reserved.

Volume 27, Issue 3 (August-September 2023)

Back to browse issues page

Persian site map - English site map - Created in 0.06 seconds with 46 queries by YEKTAWEB 4660